A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder

International Journal of Urology

Volumn 15, Issue 9, 2008, Pages 809-815

  Homma, Yukio ^a   Yamaguchi, Takuhiro ^a   Yamaguchi, Osamu ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti muscarinic; Efficacy; Imidafenacin; Overactive bladder; Safety

Indexed keywords

IMIDAFENACIN; PLACEBO;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INCONTINENCE; JAPANESE; MALE; MICTURITION; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; URINE VOLUME; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; JAPAN; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 51349085068     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02104.x     Document Type: Article

References (18)

1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am. J. Manag. Care. 2000 6 (Suppl S580 90.
2. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999 83 : 583 90.
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003 20 : 327 36.
4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 87 : 760 6.
5. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49.
6. Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005 96 : 1314 8.
7. Yamaguchi O. Pathophysiology of the overactive bladder and its pharmacological treatment. Folia Pharmacol. Jpn. 2003 121 : 331 8.
8. Kagawa S, Naruo S, Kojima K et al. Study of long-term administration of propiverine hydrochloride (BUP-4 tablets) for pollakiuria and urinary incontinence. Nishinihon J. Urol. 1998 60 : 57 64.
9. Yoshida M, Takahashi W, Ueda S et al. Long-term administration of propiverine hydrochloride (BUP-4 tablets) for the treatment of patients with urinary frequency and incontinence. Nishinihon J. Urol. 1997 59 : 885 92.
10. 3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung. 2007 57 : 92 100.
11. Kobayashi F, Yageta Y, Yamazaki T et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 2007 57 : 147 54.
12. Murakami S, Yoshida M, Iwashita H et al. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol. Int. 2003 71 : 290 8.
13. Homma Y, Gotoh M, Ando T, Fukuhara S. Development of Japanese version of QOL questionnaires for urinary incontinence. J. Neurogenic Bladder Soc. 1999 10 : 225 36.
14. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of anti-muscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. 2005 48 : 5 26.
15. Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003 92 : 741 7.
16. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. 2003 78 : 687 95.
17. Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int. Urogynecol. J. Pelvic. Floor Dysfunct. 2006 17 : 512 9.
18. Andersson KE. Anti-muscarinics for treatment of overactive bladder. Lancet Neurol. 2004 3 : 46 53.